Research programme: small molecule therapeutics - Insilico Medicine/Usynova Pharmaceuticals
Latest Information Update: 24 Aug 2021
At a glance
- Originator Usynova Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Cancer
Most Recent Events
- 05 Aug 2021 Usynova Pharmaceuticals enters into collaboration agreement with Insilico Medicine for development of small molecule therapeutics in Cancer and autoimmune diseases
- 05 Aug 2021 Early research in Autoimmune disorders in China (unspecified route)
- 05 Aug 2021 Early research in Cancer in China (unspecified route)